{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-037687","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.742549+00:00","generated_at":"2026-06-15T11:27:41.683934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly","bullets":["Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.","Non-GAAP net loss of $47.3M ($0.25/share) excluding $89.7M in impairment charges.","Revenue $21.6M, down from $24.8M; R&D expense fell to $30.5M from $107.3M.","Cash and investments $456.8M; expected to fund operations into mid-2026.","Regained full rights to rezpegaldesleukin from Eli Lilly; plans Phase 2b atopic dermatitis study."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-037687","json":"https://secwatch.observer/filing/0001213900-23-037687.json","markdown":"https://secwatch.observer/filing/0001213900-23-037687.md","text":"https://secwatch.observer/filing/0001213900-23-037687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/0001213900-23-037687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/ea178178-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:27:41.683934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b0ed5865d48a09e7d2f74fd2988a12020f38fb7","claim":"NEKTAR THERAPEUTICS reported first quarter ended March 31, 2023 results: revenue $21.6 million, net income $137.0 million, EPS $0.73 basic and diluted loss per share.","evidence_excerpt":"to advance our immunology research pipeline with the goal of advancing a new IND candidate next year.” Summary of Financial Results Revenue in the first quarter of 2023 was $21.6 million as compared to $24.8 million in the first quarter of 2022. Total operating costs and expenses in the first quarter of 2023 were $156.3 million as compared to $141.4 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/0001213900-23-037687-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$21.6 million"},{"label":"Net income","value":"$137.0 million"},{"label":"EPS","value":"$0.73 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}